Loading
For stage III lung cancers with an EGFR mutation, a targeted pill after chemoradiation cut progression by more than 80%.
LAURA, trial NCT03521154 sponsored by AstraZeneca and reported in 2024, showed that for unresectable stage III EGFR-mutant non-small-cell lung cancer, osimertinib after chemoradiation cuts the risk of progression by more than eighty percent compared with placebo. It enrolled 216 patients, met its primary progression-free survival endpoint by blinded review with a very large effect, and led to FDA approval in September 2024, replacing durvalumab consolidation in EGFR-mutant stage III disease. OnCo links it to EGFR as a target and to osimertinib, and the result is consistent with ADAURA in showing a large EGFR inhibitor benefit after local therapy. Overall survival is immature, the trial has no independent replication, and whether indefinite osimertinib is needed or a fixed course would do is the open question. Osimertinib has its own page.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
216 enrolled.
Step lines join published landmark estimates; the true curve between them is not shown.
Curves show the trial population; they are not a prediction for any one person.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (BICR)primary | Osimertinib | 143 | 39.1 months | 0.16 (0.1 to 0.24) | <0.001 | link |
| Placebo | 73 | 5.6 months |
Shares Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models, Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Unresectable stage III non-small-cell lung cancer, Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, AstraZeneca, Small-molecule kinase inhibitors.
Shares Autonomous closed-loop adaptive therapy driven by blood tests and evolutionary models, Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Osimertinib, AstraZeneca, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer.
Shares Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC, Unresectable stage III non-small-cell lung cancer, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.